Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 32-35

  Mukai, Hirofumi ^a   Katsumata, Noriyuki ^b   Ando, Masashi ^b   Watanabe, Toru ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Hamamatsu Oncology Center   (Japan)

Author keywords

Cisplatin; Clinical trial; Docetaxel; Safety and efficacy; Unknown primary cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GRANISETRON; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; SIDE EFFECT; SOFT TISSUE METASTASIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS; VOMITING; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; YOUNG ADULT;

EID: 76749151869     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819ccc55     Document Type: Article

References (20)

1. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280.
2. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol. 1977;4:53-58.
3. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:2537-2560.
4. Eagan RT, Therneau TM, Rubin J, et al. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol. 1987;10:82-85.
5. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
6. Ravdin PM. Docetaxel (Taxotere) for the treatment of anthracycline- resistant breast cancer. Semin Oncol. 1997;24:S10-S21.
7. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58-65.
8. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13:2886-2894.
9. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer. 1997;33:2167-2170.
10. Mukai H, Watanabe T, Ando M, et al. Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. Int J Clin Oncol. 2003;8:23-25.
11. Farrugia DC, Norman AR, Nicolson MC, et al. Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits. Eur J Cancer. 1996;32A:2256-2261.
12. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211-215.
13. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication 48. Geneva, Switzerland: World Health Organization; 1979.
14. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
15. Kaplan E, Meire P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Vasey PA, Paul J, Birt A, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol. 1999;17:2069-2080.
17. Pronk LC, Schellens JH, Planting AS, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol. 1997;15:1071-1079.
18. Karato A, Hayashi I, Segawa Y. Phase I/II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small lung cancer. Lung Cancer. 1997;18:30.
19. Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997; 15:2056-2066.
20. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000;18:3101-3107.